Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | V560_L576del |
Impact List | deletion |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | KIT V560_L576del results in the deletion of 17 amino acids in the juxtamembrane domain (exon 11) of the Kit protein from amino acids 560 to 576 (PMID: 16226710). V560_L576del has not been characterized, however similar Kit exon 11 deletions are activating (PMID: 9438854, PMID: 15365079), and therefore, is predicted to lead to a gain of Kit protein function. |
Associated Drug Resistance | |
Category Variants Paths |
KIT mutant KIT act mut KIT exon 11 del KIT V560_L576del KIT mutant KIT exon11 KIT exon 11 del KIT V560_L576del |
Transcript | NM_000222.3 |
gDNA | chr4:g.54727446_54727496del51 |
cDNA | c.1678_1728del51 |
Protein | p.V560_L576del17 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_005265740.1 | chr4:g.54727443_54727493del51 | c.1678_1728del51 | p.V560_Q576del17 | RefSeq | GRCh38/hg38 |
NM_000222 | chr4:g.54727446_54727496del51 | c.1678_1728del51 | p.V560_L576del17 | RefSeq | GRCh38/hg38 |
XM_017008180 | chr4:g.54727460_54727510del51 | c.1680_1730del51 | p.N560_H576del17 | RefSeq | GRCh38/hg38 |
NM_001093772 | chr4:g.54727460_54727510del51 | c.1680_1730del51 | p.N560_H576del17 | RefSeq | GRCh38/hg38 |
XM_005265741 | chr4:g.54727443_54727493del51 | c.1678_1728del51 | p.V560_Q576del17 | RefSeq | GRCh38/hg38 |
NM_001093772.1 | chr4:g.54727460_54727510del51 | c.1680_1730del51 | p.N560_H576del17 | RefSeq | GRCh38/hg38 |
NM_001093772.2 | chr4:g.54727460_54727510del51 | c.1680_1730del51 | p.N560_H576del17 | RefSeq | GRCh38/hg38 |
NM_000222.2 | chr4:g.54727446_54727496del51 | c.1678_1728del51 | p.V560_L576del17 | RefSeq | GRCh38/hg38 |
XM_005265741.1 | chr4:g.54727443_54727493del51 | c.1678_1728del51 | p.V560_Q576del17 | RefSeq | GRCh38/hg38 |
XM_017008180.1 | chr4:g.54727460_54727510del51 | c.1680_1730del51 | p.N560_H576del17 | RefSeq | GRCh38/hg38 |
NM_001385288.1 | chr4:g.54727455_54727505del51 | c.1678_1728del51 | p.I560_D576del17 | RefSeq | GRCh38/hg38 |
NM_001385286.1 | chr4:g.54727460_54727510del51 | c.1680_1730del51 | p.N560_H576del17 | RefSeq | GRCh38/hg38 |
XM_005265742.3 | chr4:g.54727455_54727505del51 | c.1678_1728del51 | p.I560_D576del17 | RefSeq | GRCh38/hg38 |
XM_017008178.1 | chr4:g.54727446_54727496del51 | c.1678_1728del51 | p.V560_L576del17 | RefSeq | GRCh38/hg38 |
NM_001385285.1 | chr4:g.54727446_54727496del51 | c.1678_1728del51 | p.V560_L576del17 | RefSeq | GRCh38/hg38 |
XM_017008178 | chr4:g.54727446_54727496del51 | c.1678_1728del51 | p.V560_L576del17 | RefSeq | GRCh38/hg38 |
XM_017008179.1 | chr4:g.54727455_54727505del51 | c.1678_1728del51 | p.I560_D576del17 | RefSeq | GRCh38/hg38 |
XM_005265740 | chr4:g.54727443_54727493del51 | c.1678_1728del51 | p.V560_Q576del17 | RefSeq | GRCh38/hg38 |
XM_005265742 | chr4:g.54727455_54727505del51 | c.1678_1728del51 | p.I560_D576del17 | RefSeq | GRCh38/hg38 |
NM_001385284.1 | chr4:g.54727443_54727493del51 | c.1678_1728del51 | p.V560_Q576del17 | RefSeq | GRCh38/hg38 |
NM_000222.3 | chr4:g.54727446_54727496del51 | c.1678_1728del51 | p.V560_L576del17 | RefSeq | GRCh38/hg38 |
XM_017008179 | chr4:g.54727455_54727505del51 | c.1678_1728del51 | p.I560_D576del17 | RefSeq | GRCh38/hg38 |
NM_001385290.1 | chr4:g.54727443_54727493del51 | c.1678_1728del51 | p.V560_Q576del17 | RefSeq | GRCh38/hg38 |
NM_001385292.1 | chr4:g.54727455_54727505del51 | c.1678_1728del51 | p.I560_D576del17 | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|